SCM
ENTX icon

Superstring Capital Management’s Entera Bio ENTX Stock Holding History

Superstring Capital Management’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,142
Closed -$33.3K – 43
2025
Q4 		$33.3K Buy
+17,142
New +$40.2K 0.02% 45

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

Superstring Capital Management's ENTX Position: Q1 2026 in Review

Superstring Capital Management sold out of Entera Bio (ENTX) in Q1 2026, closing a stake of 17,142 shares — an estimated $33.3K sold.

Superstring Capital Management first reported a position in ENTX in Q4 2025 and held it in 1 quarter. The position peaked at $33.3K in Q4 2025. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • Superstring Capital Management reported no remaining Entera Bio position as of Q1 2026 after selling out during the quarter.
  • Superstring Capital Management sold 17,142 Entera Bio shares in Q1 2026, an estimated $33.3K.
  • Superstring Capital Management first reported a position in Entera Bio in Q4 2025 and held it in 1 quarter.
  • Superstring Capital Management's Entera Bio position peaked at $33.3K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.